Drug intelligence / Profile preview

SNO8

Development stage: Preclinical
Lead developer: University of Iceland
Modality: Small Molecules

Overview

SNO8 is a novel organotin chloride compound developed by researchers at the University of Iceland. It is being investigated for its cytotoxic activity against various cancer cell lines, including breast (T47-D), lung (A549), ovarian (OVCAR-3), and pancreatic (Aspc-1) cancers. In preclinical studies, SNO8 demonstrated the ability to induce apoptosis, with IC50 values comparable to or more potent than cisplatin in certain cell lines. The compound is part of a research effort to identify metal-containing alternatives to platinum-based therapies that may overcome resistance mechanisms.

Beyond the preview

Go deeper on SNO8.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNO8.

Explore the full profile